Alemtuzumab, an anti-CD52 monoclonal antibody was applied successfully to B cell chronic lymphocytic leukemia (B-CLL) patients since 2001, but was only secondarily tested in MCL without a break-through [42,43]. Here, CD52 is linked to mantle cell lymphoma.